1
00:00:02,200 --> 00:00:05,199
Speaker 1: If you or maybe your kid has needed a prescription

2
00:00:05,360 --> 00:00:09,800
Speaker 1: for the popular antibiotic amoxicillin lately. You know that's the

3
00:00:10,000 --> 00:00:12,680
Speaker 1: bright pink one, Well, you might have had a hard

4
00:00:12,720 --> 00:00:16,360
Speaker 1: time finding a pharmacy that has it on hand, or

5
00:00:16,440 --> 00:00:20,360
Speaker 1: any number of other generic medications for that matter. Bloomberg's

6
00:00:20,360 --> 00:00:23,400
Speaker 1: Ike Sweatlts reports that some of the most in demand

7
00:00:23,480 --> 00:00:27,200
Speaker 1: generics in the US are increasingly in short supply.

8
00:00:27,880 --> 00:00:30,680
Speaker 2: What's significant now is that there's a lot of shortages

9
00:00:30,760 --> 00:00:33,839
Speaker 2: in a lot of different areas that are all affecting patients.

10
00:00:33,840 --> 00:00:35,840
Speaker 2: So you have the cancer drugs, you have the antibiotics,

11
00:00:35,840 --> 00:00:39,400
Speaker 2: you have the ADHD medicines. Each of these areas has

12
00:00:39,479 --> 00:00:43,440
Speaker 2: seen issues and challenges before. What's unique now is sort

13
00:00:43,479 --> 00:00:44,920
Speaker 2: of all happening at the same time.

14
00:00:45,560 --> 00:00:49,800
Speaker 1: Ike's here to explain why that is, and Health Security

15
00:00:49,880 --> 00:00:52,960
Speaker 1: reporter Riley Griffin is back to tell us what the

16
00:00:53,120 --> 00:00:56,360
Speaker 1: US government is doing to try to fix this growing problem.

17
00:00:56,840 --> 00:00:58,880
Speaker 3: But it remains to be seen whether or not they

18
00:00:58,880 --> 00:01:02,720
Speaker 3: will achieve something at the scale of say the Chips Act,

19
00:01:02,960 --> 00:01:06,400
Speaker 3: which was about bringing chips production back here to the

20
00:01:06,480 --> 00:01:10,319
Speaker 3: United States. But we have not seen a Chips for pharma.

21
00:01:10,440 --> 00:01:13,320
Speaker 3: Despite people advocating for it, and despite folks at the

22
00:01:13,360 --> 00:01:17,520
Speaker 3: White House really thinking critically about all the different ways

23
00:01:17,560 --> 00:01:25,000
Speaker 3: to approach this problem.

24
00:01:25,319 --> 00:01:36,319
Speaker 1: I'm Wescasova today on the big take the generic drug dilemma.

25
00:01:38,640 --> 00:01:41,160
Speaker 1: Let me just start by asking you the big question,

26
00:01:41,240 --> 00:01:45,200
Speaker 1: what is causing this shortage of generic drugs in the US.

27
00:01:46,040 --> 00:01:49,559
Speaker 2: There have been shortages of generic drugs in the US

28
00:01:49,760 --> 00:01:54,960
Speaker 2: really for over a decade. There are individual events that

29
00:01:55,040 --> 00:01:59,280
Speaker 2: might prompt each shortage, whether it's a hurricane or a

30
00:01:59,280 --> 00:02:02,400
Speaker 2: plant that has to shut down or stop manufacturing because

31
00:02:02,520 --> 00:02:05,520
Speaker 2: there was some safety or quality issue.

32
00:02:05,160 --> 00:02:05,880
Speaker 4: With the drugs.

33
00:02:06,200 --> 00:02:09,200
Speaker 2: But behind all of those is the fact that a

34
00:02:09,320 --> 00:02:13,359
Speaker 2: lot of generic drugs don't make a lot of money,

35
00:02:13,440 --> 00:02:16,240
Speaker 2: if any money at all, for the manufacturers. And if

36
00:02:16,280 --> 00:02:19,000
Speaker 2: you have a product that doesn't make a lot of money,

37
00:02:19,160 --> 00:02:24,120
Speaker 2: there's not a huge financial incentive to maintain a robust,

38
00:02:24,360 --> 00:02:29,520
Speaker 2: reliable supply chain with a lot of extra empty manufacturing

39
00:02:29,520 --> 00:02:33,120
Speaker 2: capacity that you can quickly use when something goes wrong.

40
00:02:34,760 --> 00:02:37,360
Speaker 1: Generic drugs have been around for a long time and

41
00:02:37,480 --> 00:02:40,200
Speaker 1: manufacturers have been able to turn a profit making them.

42
00:02:40,440 --> 00:02:44,600
Speaker 1: Why have they become unprofitable now to the point where

43
00:02:44,720 --> 00:02:46,280
Speaker 1: there are shortages.

44
00:02:46,560 --> 00:02:50,280
Speaker 2: When the idea of generic drugs was introduced. You know,

45
00:02:50,320 --> 00:02:52,960
Speaker 2: it was supposed to be that the company that invented

46
00:02:53,000 --> 00:02:55,320
Speaker 2: a medicine was going to get some sort of patent

47
00:02:55,320 --> 00:02:56,600
Speaker 2: protection on it for a little while.

48
00:02:57,080 --> 00:02:59,440
Speaker 4: They make a lot of money during that time.

49
00:02:59,240 --> 00:03:03,080
Speaker 2: To recoup their research and development costs, and then the

50
00:03:03,160 --> 00:03:06,000
Speaker 2: drug goes generic. A lot of other companies can enter

51
00:03:06,000 --> 00:03:08,799
Speaker 2: the market and produce their own versions at a much

52
00:03:08,800 --> 00:03:11,919
Speaker 2: lower cost of patients. The whole idea behind generic drugs

53
00:03:11,960 --> 00:03:14,160
Speaker 2: is that they're supposed to be cheaper for patients.

54
00:03:14,639 --> 00:03:16,480
Speaker 4: The problem comes when.

55
00:03:16,639 --> 00:03:19,680
Speaker 2: The cost of the generic drugs falls so low that

56
00:03:19,760 --> 00:03:24,079
Speaker 2: their manufacturers can't cover their cost of production. And there

57
00:03:24,080 --> 00:03:26,799
Speaker 2: are a lot of reasons why prices and cost of

58
00:03:26,840 --> 00:03:29,720
Speaker 2: generic drugs have been going down and down. Partially, it's

59
00:03:29,720 --> 00:03:33,360
Speaker 2: sort of baked into the system. So all generic amoxicillin,

60
00:03:33,440 --> 00:03:36,240
Speaker 2: for example, this antibiotic the most popular antibiotic in the

61
00:03:36,320 --> 00:03:39,880
Speaker 2: United States. They're all supposed to be equivalent to each other.

62
00:03:39,920 --> 00:03:41,960
Speaker 2: That's what the FDA says. You go into a pharmacy,

63
00:03:41,960 --> 00:03:44,680
Speaker 2: you fill a prescription for amoxicillin. You don't ask for

64
00:03:44,840 --> 00:03:47,640
Speaker 2: a ma oxiscillin from this manufacturer that manufacturer. You just

65
00:03:47,680 --> 00:03:50,440
Speaker 2: fill the prescription. They give you whatever generic they happen

66
00:03:50,480 --> 00:03:53,800
Speaker 2: to have. So the only thing that generic drugs are

67
00:03:53,800 --> 00:03:57,960
Speaker 2: really competing on is on the price. There's also consolidation

68
00:03:58,120 --> 00:04:03,640
Speaker 2: among the companies that per chis generic drugs, especially for pharmacies.

69
00:04:04,200 --> 00:04:06,520
Speaker 4: So there's basically.

70
00:04:06,200 --> 00:04:10,960
Speaker 2: Three or four large buying groups that buy about ninety

71
00:04:11,040 --> 00:04:15,000
Speaker 2: percent of all of the generic drugs that are dispensed

72
00:04:15,120 --> 00:04:19,560
Speaker 2: in retail pharmacies you know, CVS Walgreens in the United States,

73
00:04:19,880 --> 00:04:22,479
Speaker 2: And because there's only a handful of them, they have

74
00:04:22,560 --> 00:04:25,119
Speaker 2: a lot of power in the market, and that power

75
00:04:25,360 --> 00:04:28,560
Speaker 2: helps drive down the cost and price of those drugs.

76
00:04:29,080 --> 00:04:31,520
Speaker 1: Like like you mentioned, amoxicillin is one of the drugs

77
00:04:31,560 --> 00:04:34,120
Speaker 1: that's in short supply. I think anyone who's had a

78
00:04:34,200 --> 00:04:37,000
Speaker 1: kid or was a kid knows all about a maxicillin.

79
00:04:37,200 --> 00:04:40,120
Speaker 1: It's so widely used. But what other medicines are also

80
00:04:40,200 --> 00:04:41,000
Speaker 1: in short supply.

81
00:04:41,800 --> 00:04:45,160
Speaker 2: There's a lot of cancer drugs, chemotherapy, medicines that are

82
00:04:45,160 --> 00:04:48,320
Speaker 2: in short supply right now. That's one big category. Then

83
00:04:48,360 --> 00:04:51,159
Speaker 2: there's the drugs that you pick up at the pharmacy, antibiotics,

84
00:04:51,320 --> 00:04:55,200
Speaker 2: a lot of medicines for ADHD, other antibiotics other than

85
00:04:55,240 --> 00:04:57,600
Speaker 2: a maxicillin. You know, the latest data that we have

86
00:04:57,800 --> 00:05:01,039
Speaker 2: from the University of Utah's service, there tracking three hundred

87
00:05:01,080 --> 00:05:04,040
Speaker 2: and five drugs that are in short supply. That's the

88
00:05:04,120 --> 00:05:08,520
Speaker 2: highest it's been since twenty fourteen. But what's significant now

89
00:05:08,600 --> 00:05:10,800
Speaker 2: is that there's a lot of shortages in a lot

90
00:05:10,839 --> 00:05:13,640
Speaker 2: of different areas that are all affecting patients. So you

91
00:05:13,680 --> 00:05:15,599
Speaker 2: have the cancer drugs, you have the antibiotics, you have

92
00:05:15,640 --> 00:05:19,919
Speaker 2: the ADHD medicines. Each of these areas has seen issues

93
00:05:19,960 --> 00:05:23,400
Speaker 2: and challenges before. What's unique now is sort of all

94
00:05:23,440 --> 00:05:24,520
Speaker 2: happening at the same time.

95
00:05:25,360 --> 00:05:27,800
Speaker 1: And you report that part of the challenge for US

96
00:05:27,839 --> 00:05:32,520
Speaker 1: manufacturers is increased competition from overseas, where they're able to

97
00:05:32,760 --> 00:05:36,320
Speaker 1: get the ingredients and manufacture the drugs much more cheaply.

98
00:05:37,040 --> 00:05:41,279
Speaker 2: Yeah, there are different labor costs, there's different energy costs.

99
00:05:41,640 --> 00:05:44,640
Speaker 2: That's sort of been happening, i would say over the

100
00:05:44,680 --> 00:05:48,279
Speaker 2: past few decades. That's not something that's just new right now,

101
00:05:48,720 --> 00:05:52,240
Speaker 2: but that is definitely something that has on one hand,

102
00:05:52,320 --> 00:05:56,000
Speaker 2: made a lot of these medicines more accessible physically and

103
00:05:56,040 --> 00:05:58,760
Speaker 2: financially for people all around the world. It's also made

104
00:05:58,760 --> 00:06:01,960
Speaker 2: it more difficult for some manuft as to keep up

105
00:06:02,000 --> 00:06:05,360
Speaker 2: financially and keep producing the drugs, and.

106
00:06:05,320 --> 00:06:07,359
Speaker 1: So why is it important that these drugs have to

107
00:06:07,360 --> 00:06:09,960
Speaker 1: come from US makers. Why can't we just shift to

108
00:06:10,360 --> 00:06:14,440
Speaker 1: buying more foreign antibiotics and other drugs.

109
00:06:15,120 --> 00:06:17,919
Speaker 2: Well, that depends on who you ask, So some people

110
00:06:17,920 --> 00:06:19,520
Speaker 2: would say that that's totally fine.

111
00:06:19,560 --> 00:06:21,560
Speaker 4: You know, that's just part of the globalized supply chain.

112
00:06:21,960 --> 00:06:24,320
Speaker 2: Things are made in different places, and what we really

113
00:06:24,360 --> 00:06:28,360
Speaker 2: need to do is work to reduce the barriers from

114
00:06:28,440 --> 00:06:31,839
Speaker 2: getting the medicines from point A to point B. Another

115
00:06:31,920 --> 00:06:34,000
Speaker 2: argument is that it's important for countries to be able

116
00:06:34,040 --> 00:06:36,480
Speaker 2: to provide medicines for the health and well being of

117
00:06:36,520 --> 00:06:40,839
Speaker 2: the people who live there and in times of international

118
00:06:40,880 --> 00:06:45,520
Speaker 2: conflict or international crisis global pandemic, for example, we saw

119
00:06:45,800 --> 00:06:50,200
Speaker 2: earlier in COVID some countries restricting the export of medical products,

120
00:06:50,760 --> 00:06:55,400
Speaker 2: and so having medicines and having the ingredients to make

121
00:06:55,400 --> 00:06:58,760
Speaker 2: those medicines available in the country might be helpful in

122
00:06:58,760 --> 00:07:03,080
Speaker 2: that situation, or having policies that would allow those products

123
00:07:03,080 --> 00:07:06,040
Speaker 2: to be bought and sold even in those more extreme situations.

124
00:07:06,839 --> 00:07:12,720
Speaker 2: More domestic manufacturing of generic drugs is not something that

125
00:07:12,840 --> 00:07:16,080
Speaker 2: everyone is calling for as a solution to these drug shortages.

126
00:07:16,400 --> 00:07:20,520
Speaker 2: In fact, people are pointing out that domestic US manufacturing

127
00:07:20,520 --> 00:07:24,360
Speaker 2: plants can have the same problems that plants outside the

128
00:07:24,440 --> 00:07:25,320
Speaker 2: United States can have.

129
00:07:26,280 --> 00:07:29,200
Speaker 1: And so what are the practical effects of having these shortages.

130
00:07:29,720 --> 00:07:31,880
Speaker 1: Do you have to just switch to a different kind

131
00:07:31,880 --> 00:07:34,440
Speaker 1: of say, antibiotic, or are you just able to find it

132
00:07:34,480 --> 00:07:36,360
Speaker 1: overseas even if you aren't able to find it in

133
00:07:36,400 --> 00:07:36,880
Speaker 1: the US.

134
00:07:37,720 --> 00:07:40,400
Speaker 4: So it depends on what sort of medicine it is.

135
00:07:40,680 --> 00:07:45,680
Speaker 2: So for antibiotics, there are other antibiotics other than amoxicillin,

136
00:07:45,760 --> 00:07:50,360
Speaker 2: for example. The problem is last year, when a lot

137
00:07:50,360 --> 00:07:53,880
Speaker 2: of these maxicillin shortages started, the companies that make those

138
00:07:54,000 --> 00:07:58,000
Speaker 2: other antibiotics were not anticipating in a maxicillin shortage that

139
00:07:58,000 --> 00:08:00,320
Speaker 2: would then lead to a run on their products. So

140
00:08:00,760 --> 00:08:04,920
Speaker 2: when patients couldn't find a ma oxicillin, their doctor might

141
00:08:04,920 --> 00:08:07,520
Speaker 2: give them a prescription for another type of antibiotics, say

142
00:08:07,560 --> 00:08:10,720
Speaker 2: a different kind of penicillin. But then people started filling

143
00:08:10,720 --> 00:08:13,600
Speaker 2: those prescriptions for all those penicillins. After that, then there

144
00:08:13,680 --> 00:08:16,520
Speaker 2: was a diminished supply of those penicillins, and one of

145
00:08:16,520 --> 00:08:21,840
Speaker 2: those is basically the only treatment for pregnant people with syphilis.

146
00:08:22,040 --> 00:08:26,160
Speaker 2: And now that penicillin is a lot harder to find

147
00:08:26,520 --> 00:08:29,560
Speaker 2: and making it more difficult to treat those folks. So

148
00:08:29,600 --> 00:08:31,760
Speaker 2: there's sort of those like knock on effects of yeah,

149
00:08:31,800 --> 00:08:34,480
Speaker 2: maybe in an individual case you can fill the prescription

150
00:08:34,520 --> 00:08:38,000
Speaker 2: with something else, but that leads to a shortage down

151
00:08:38,080 --> 00:08:41,320
Speaker 2: the road. There's another problem, especially with antibiotics, which is

152
00:08:41,760 --> 00:08:43,000
Speaker 2: that you're really.

153
00:08:42,800 --> 00:08:45,840
Speaker 4: Supposed to use the most specific.

154
00:08:45,320 --> 00:08:48,440
Speaker 2: Antibiotic that you can because you want the antibiotic to

155
00:08:48,600 --> 00:08:50,559
Speaker 2: kill the bacteria that you've got.

156
00:08:51,160 --> 00:08:52,520
Speaker 4: You don't really want it to do anything else.

157
00:08:52,920 --> 00:08:56,520
Speaker 2: If you use sort of a general antibiotic that's maybe

158
00:08:56,559 --> 00:08:59,679
Speaker 2: not quite as good at killing that particular bacteria, what

159
00:08:59,679 --> 00:09:04,640
Speaker 2: happens is the bacteria will develop resistance to that antabatic,

160
00:09:05,000 --> 00:09:07,920
Speaker 2: and then that antibatic becomes much less effective in the future.

161
00:09:10,080 --> 00:09:13,040
Speaker 1: In your reporting, you write about an American company called

162
00:09:13,200 --> 00:09:16,800
Speaker 1: US Antibiotics, and they're facing a lot of the things

163
00:09:16,800 --> 00:09:19,559
Speaker 1: you're describing here. Can you tell us about that company?

164
00:09:19,840 --> 00:09:22,280
Speaker 2: So that company started a few years ago when they

165
00:09:22,320 --> 00:09:26,720
Speaker 2: purchased what at the time was the only plant in

166
00:09:26,760 --> 00:09:30,400
Speaker 2: the United States making a maxicillin. That plant used to

167
00:09:30,440 --> 00:09:33,640
Speaker 2: make enough a maxicillin for everyone in the United States

168
00:09:33,679 --> 00:09:37,480
Speaker 2: who needed it. It was opened in the seventies in Bristol, Tennessee.

169
00:09:37,960 --> 00:09:40,800
Speaker 2: You know what, its peak had five hundred or so employees.

170
00:09:41,280 --> 00:09:45,800
Speaker 2: Back then, this was a brand product, more financially lucrative.

171
00:09:46,280 --> 00:09:49,640
Speaker 2: The drugs went generic. The plant changed hands a few

172
00:09:49,640 --> 00:09:53,080
Speaker 2: times over the past fifteen years, and the company that

173
00:09:53,120 --> 00:09:55,880
Speaker 2: owned it most recently before US Antabatics a few years

174
00:09:55,880 --> 00:09:59,760
Speaker 2: ago went into bankruptcy and US Antibiotics bought the plant

175
00:09:59,760 --> 00:10:03,520
Speaker 2: out that they knew that this was going to be

176
00:10:03,920 --> 00:10:08,040
Speaker 2: a challenge. The company that bought it is a subsidiary

177
00:10:08,160 --> 00:10:11,600
Speaker 2: of Jackson Healthcare, which is mostly a medical staffing company.

178
00:10:11,880 --> 00:10:14,960
Speaker 2: And Rick Jackson, who runs Jackson Healthcare, told me he

179
00:10:15,040 --> 00:10:18,040
Speaker 2: bought this sort of more out of what he felt

180
00:10:18,080 --> 00:10:20,080
Speaker 2: was like a civic duty to keep it open and

181
00:10:20,120 --> 00:10:22,840
Speaker 2: keep it running. He bought this plant knowing that it

182
00:10:22,920 --> 00:10:25,920
Speaker 2: might not be the best business opportunity, but he wanted

183
00:10:25,920 --> 00:10:28,720
Speaker 2: to make sure that a marxicillin was going to continue

184
00:10:28,760 --> 00:10:30,360
Speaker 2: to be produced in the United States.

185
00:10:30,960 --> 00:10:32,480
Speaker 1: And how'd that work out for him?

186
00:10:32,800 --> 00:10:35,360
Speaker 2: Well, so far, the plant, you know, it's still running.

187
00:10:35,720 --> 00:10:38,120
Speaker 2: He said that it's losing a lot of money, and

188
00:10:38,200 --> 00:10:42,160
Speaker 2: he is hoping that the US government will commit to

189
00:10:42,200 --> 00:10:45,720
Speaker 2: purchasing drugs from there to sort of provide a dedicated

190
00:10:45,720 --> 00:10:48,679
Speaker 2: revenue stream and allow him to keep it open.

191
00:10:49,000 --> 00:10:51,360
Speaker 4: And the future of this plant really hinges on that.

192
00:10:52,160 --> 00:10:54,120
Speaker 1: And you went to see this plant, where was it?

193
00:10:54,200 --> 00:10:56,600
Speaker 4: Like? It's a giant facility.

194
00:10:56,640 --> 00:10:59,839
Speaker 2: I think it's three hundred and ninety four thousand square

195
00:11:00,480 --> 00:11:03,360
Speaker 2: I've been writing for months about how patients hadn't been

196
00:11:03,360 --> 00:11:05,680
Speaker 2: able to fill prescriptions, and I go and see a

197
00:11:05,760 --> 00:11:09,800
Speaker 2: huge amount of the active pharmaceutical ingredient in the warehouse there.

198
00:11:10,240 --> 00:11:13,240
Speaker 2: It was a pretty empty place compared to what it

199
00:11:13,280 --> 00:11:15,480
Speaker 2: could be. There was equipment there that was just sitting

200
00:11:15,559 --> 00:11:18,280
Speaker 2: under plastic. It wasn't being used anymore. There were areas

201
00:11:18,320 --> 00:11:21,040
Speaker 2: of the plant that had been closed off a while ago.

202
00:11:21,600 --> 00:11:23,839
Speaker 2: This is a highly regulated field and there's a lot

203
00:11:23,880 --> 00:11:26,160
Speaker 2: of things you have to do in exactly the right

204
00:11:26,200 --> 00:11:29,360
Speaker 2: way all the time, and that costs money, and that

205
00:11:29,400 --> 00:11:30,640
Speaker 2: takes time to train people to do.

206
00:11:32,120 --> 00:11:35,680
Speaker 1: So if they're losing money, how can they continue to

207
00:11:35,720 --> 00:11:36,679
Speaker 1: stay in business?

208
00:11:37,320 --> 00:11:41,120
Speaker 2: Rick Jackson Jackson Healthcare said he's providing funds for this,

209
00:11:41,240 --> 00:11:44,000
Speaker 2: but he's not going to subsidize it forever. So I

210
00:11:44,040 --> 00:11:47,840
Speaker 2: think that the future of the plant is up to

211
00:11:48,480 --> 00:11:50,920
Speaker 2: how much money they're able to make selling to the

212
00:11:50,920 --> 00:11:56,120
Speaker 2: government or selling to drug distributors in the commercial market.

213
00:11:56,280 --> 00:11:59,080
Speaker 1: After the break. Is the US the only country facing

214
00:11:59,200 --> 00:12:08,880
Speaker 1: this drug shortage problem? We hear a lot of these

215
00:12:08,960 --> 00:12:12,679
Speaker 1: days about the Biden administrations push to bring manufacturing back

216
00:12:12,720 --> 00:12:17,240
Speaker 1: to the US computer chips, electric vehicles, and batteries. Are

217
00:12:17,280 --> 00:12:20,160
Speaker 1: there any incentives like this where the US government is

218
00:12:20,160 --> 00:12:23,960
Speaker 1: giving money to pharmaceutical companies drug manufacturers to make these

219
00:12:24,040 --> 00:12:25,560
Speaker 1: kinds of drugs that are in short supply.

220
00:12:26,360 --> 00:12:26,640
Speaker 4: Yeah.

221
00:12:26,720 --> 00:12:33,559
Speaker 2: The Biden administration has said that domestic production of pharmaceuticals,

222
00:12:33,559 --> 00:12:37,679
Speaker 2: of medicines, and of the raw ingredients are critical. When

223
00:12:37,720 --> 00:12:41,559
Speaker 2: they announced the Infrastructure Plan several years ago, talking about

224
00:12:41,840 --> 00:12:45,960
Speaker 2: the need for more support for semiconductors for electric vehicle batteries,

225
00:12:46,320 --> 00:12:50,800
Speaker 2: they included pharmaceuticals and medicines in that push. We haven't

226
00:12:50,920 --> 00:12:55,280
Speaker 2: yet seen the large, multi billion dollar subsidy packages coming

227
00:12:55,280 --> 00:12:57,240
Speaker 2: out of Congress to support that in a way that

228
00:12:57,280 --> 00:13:00,600
Speaker 2: we have for batteries and forced conductors.

229
00:13:00,880 --> 00:13:01,400
Speaker 4: I've talked to.

230
00:13:01,320 --> 00:13:05,160
Speaker 2: Folks about this, and one reason people have given is

231
00:13:05,200 --> 00:13:11,080
Speaker 2: that it is politically unpopular to support the drug industry.

232
00:13:11,440 --> 00:13:14,880
Speaker 2: And there's been a lot of attention over the last

233
00:13:14,920 --> 00:13:19,400
Speaker 2: several years on high drug prices, often those high drug

234
00:13:19,440 --> 00:13:23,440
Speaker 2: prices are brand medicines protected by patents.

235
00:13:23,840 --> 00:13:27,280
Speaker 4: New drugs or maybe old drugs, they're still protected by patents.

236
00:13:27,520 --> 00:13:30,680
Speaker 2: So politicians have been doing a lot to try to

237
00:13:30,760 --> 00:13:34,240
Speaker 2: reduce the cost of health care. Healthcare is incredibly expensive

238
00:13:34,240 --> 00:13:36,280
Speaker 2: and it might not look very good for a politician

239
00:13:36,320 --> 00:13:39,120
Speaker 2: to stand up and say, Americans, you should be paying

240
00:13:39,160 --> 00:13:42,400
Speaker 2: more for your medicines. And that makes it difficult to

241
00:13:42,920 --> 00:13:48,079
Speaker 2: get money to these manufacturers of generic drugs. So making

242
00:13:48,120 --> 00:13:50,520
Speaker 2: a lot of generic drugs in the United States would

243
00:13:50,559 --> 00:13:53,480
Speaker 2: cost more than making them outside of the United States,

244
00:13:53,679 --> 00:13:56,600
Speaker 2: and that money's got to come from somewhere. It could

245
00:13:56,600 --> 00:14:00,880
Speaker 2: come from patients paying higher insurance prema, that could come

246
00:14:00,920 --> 00:14:03,320
Speaker 2: from hospitals paying more for the drugs. It could come

247
00:14:03,360 --> 00:14:04,679
Speaker 2: from the government subsidizing it.

248
00:14:05,400 --> 00:14:07,360
Speaker 1: If the US does decide to spend some of this

249
00:14:07,400 --> 00:14:10,800
Speaker 1: money to give incentives to US manufacturers to make these

250
00:14:10,840 --> 00:14:14,319
Speaker 1: drugs in short supply, would that actually help ease the shortage.

251
00:14:15,120 --> 00:14:19,520
Speaker 2: So there are some folks who are trying to establish

252
00:14:19,840 --> 00:14:22,920
Speaker 2: manufacturing plants here and they say, we just need some

253
00:14:23,000 --> 00:14:25,040
Speaker 2: money from the government to sort of get this going,

254
00:14:25,320 --> 00:14:27,000
Speaker 2: and then once we have it going, then we can

255
00:14:27,040 --> 00:14:30,160
Speaker 2: sustain it. I think folks are worried about the government

256
00:14:30,240 --> 00:14:32,640
Speaker 2: just sort of spending a lot of money on a maxicillin, Like,

257
00:14:32,720 --> 00:14:35,280
Speaker 2: right now, here's this acute problem. The government's just going

258
00:14:35,320 --> 00:14:37,200
Speaker 2: to put all this money into it, and that might

259
00:14:37,280 --> 00:14:39,960
Speaker 2: not have the long term.

260
00:14:39,720 --> 00:14:40,920
Speaker 4: Impact people are looking for.

261
00:14:41,240 --> 00:14:44,240
Speaker 2: But I think that people are still actively debating a

262
00:14:44,240 --> 00:14:48,480
Speaker 2: lot of these proposals, and that Congress hasn't passed any legislation.

263
00:14:48,720 --> 00:14:51,080
Speaker 2: There haven't really been any big changes in the last

264
00:14:51,200 --> 00:14:51,880
Speaker 2: year or so on.

265
00:14:51,960 --> 00:14:56,200
Speaker 1: This is the US the only country that's suffering with

266
00:14:56,240 --> 00:14:59,240
Speaker 1: these kinds of shortages. What about countries in Europe, Asia

267
00:14:59,240 --> 00:14:59,880
Speaker 1: and elsewhere.

268
00:15:00,320 --> 00:15:01,880
Speaker 4: There are shortages all over the place.

269
00:15:02,240 --> 00:15:04,680
Speaker 2: Other countries in Europe have been spending money to try

270
00:15:04,680 --> 00:15:07,320
Speaker 2: and boost domestic production. And I think also important to

271
00:15:07,320 --> 00:15:10,640
Speaker 2: remember a lot of these medicines are just not available

272
00:15:10,880 --> 00:15:13,120
Speaker 2: in many parts of the world, So I think that's

273
00:15:13,120 --> 00:15:16,040
Speaker 2: an important point too, and something that low cost generic

274
00:15:16,120 --> 00:15:18,760
Speaker 2: drugs have been really good for getting medicines to places

275
00:15:18,800 --> 00:15:20,760
Speaker 2: that otherwise might not have them period.

276
00:15:21,440 --> 00:15:23,960
Speaker 1: Iik, you're watching this pretty closely as you continue to

277
00:15:24,040 --> 00:15:25,840
Speaker 1: report in the story. What are you looking for?

278
00:15:26,720 --> 00:15:30,400
Speaker 2: I am curious what the US government is going to

279
00:15:30,400 --> 00:15:34,040
Speaker 2: do and what's going to make this different than situations

280
00:15:34,080 --> 00:15:37,400
Speaker 2: we saw ten fifteen years ago. There was a big

281
00:15:37,440 --> 00:15:41,520
Speaker 2: shortage of cancer drugs. Back eleven twelve years ago or so,

282
00:15:41,840 --> 00:15:45,280
Speaker 2: there were congressional hearings, there was an executive order, there

283
00:15:45,440 --> 00:15:46,560
Speaker 2: was political attention.

284
00:15:47,120 --> 00:15:48,440
Speaker 4: Now we're seeing it again.

285
00:15:48,800 --> 00:15:52,560
Speaker 2: Right before the COVID pandemic, the FDA put out a

286
00:15:52,640 --> 00:15:55,240
Speaker 2: report looking at some of the root causes of drug shortages,

287
00:15:55,440 --> 00:15:57,600
Speaker 2: and a number of things identified in that report were

288
00:15:57,880 --> 00:16:01,600
Speaker 2: economic issues. And the FDA, who regulates the safety and

289
00:16:01,600 --> 00:16:05,360
Speaker 2: effectiveness of medicines, it's not going in and setting prices

290
00:16:05,360 --> 00:16:05,920
Speaker 2: for drugs.

291
00:16:06,160 --> 00:16:07,680
Speaker 4: I guess I'm curious what's going to be different this

292
00:16:07,720 --> 00:16:08,240
Speaker 4: time around?

293
00:16:09,040 --> 00:16:11,160
Speaker 1: Hike, thanks so much for coming on the show.

294
00:16:11,640 --> 00:16:12,440
Speaker 4: Thanks for having me.

295
00:16:15,320 --> 00:16:17,520
Speaker 1: Now let's hear what, if anything, can be done to

296
00:16:17,680 --> 00:16:23,440
Speaker 1: ease these shortages. Riley Griffin is Bloomberg's health security reporter. Riley,

297
00:16:23,480 --> 00:16:24,360
Speaker 1: it's good to see again.

298
00:16:24,560 --> 00:16:25,280
Speaker 3: Thanks for having me.

299
00:16:25,360 --> 00:16:28,480
Speaker 1: Wes, So maybe you can paint us a picture of

300
00:16:28,560 --> 00:16:31,480
Speaker 1: what the I guess you'd call it global economy for

301
00:16:31,560 --> 00:16:32,800
Speaker 1: generic drugs.

302
00:16:32,480 --> 00:16:35,680
Speaker 3: Looks like the Food and Drug Administration, our regulator here

303
00:16:35,680 --> 00:16:38,480
Speaker 3: in the US, overseas, the safety of more than two

304
00:16:38,560 --> 00:16:42,320
Speaker 3: point one trillion worth of food, tobacco, and medical products

305
00:16:42,440 --> 00:16:45,480
Speaker 3: produced in the US and abroad, and these sectors account

306
00:16:45,480 --> 00:16:49,120
Speaker 3: for one fifth of the nation's economic activity. Just picture

307
00:16:49,120 --> 00:16:51,880
Speaker 3: that for a moment, a regulator that oversees one fifth

308
00:16:52,240 --> 00:16:55,280
Speaker 3: of the nation's economic activity. So the problem is, of course,

309
00:16:55,320 --> 00:16:58,240
Speaker 3: that not all these pharmaceutical products are made in the US,

310
00:16:58,800 --> 00:17:02,400
Speaker 3: and it becomes increasingly difficult to do that oversight work

311
00:17:02,480 --> 00:17:05,240
Speaker 3: of products coming in for abroad. So I'll share some

312
00:17:05,359 --> 00:17:07,520
Speaker 3: data with you straight from the mouth of the FDA.

313
00:17:08,359 --> 00:17:11,679
Speaker 3: Seventy one percent of US biologic sales that kind of

314
00:17:11,680 --> 00:17:15,480
Speaker 3: more complex drug are actually imports. These aren't the typical

315
00:17:15,520 --> 00:17:18,159
Speaker 3: pills in your medicine cabinet, but the complex medicines you

316
00:17:18,200 --> 00:17:21,879
Speaker 3: often get in an injection developed from blood, proteins, viruses,

317
00:17:22,400 --> 00:17:26,920
Speaker 3: or living organisms. Seventy eight percent of manufacturers that make

318
00:17:27,040 --> 00:17:31,560
Speaker 3: active pharmaceutical ingredients are located outside of the United States.

319
00:17:32,080 --> 00:17:34,600
Speaker 3: And these are the materials that allow a drug to

320
00:17:34,720 --> 00:17:37,960
Speaker 3: have the desired effect in the body. It's the part

321
00:17:37,960 --> 00:17:40,560
Speaker 3: of the recipe that really makes the drug work. And

322
00:17:40,680 --> 00:17:44,440
Speaker 3: back in twenty nineteen, about one fifth of API manufacturers

323
00:17:44,440 --> 00:17:47,800
Speaker 3: were in India and thirteen percent were in China, but

324
00:17:47,880 --> 00:17:51,439
Speaker 3: that's likely to have increased since then. India's pharmaceutical industry,

325
00:17:51,440 --> 00:17:55,640
Speaker 3: for example, is only growing. It's the world's largest producer

326
00:17:55,800 --> 00:17:59,680
Speaker 3: of generic drugs, and that's a fifty billion dollar industry

327
00:18:00,000 --> 00:18:00,440
Speaker 3: over there.

328
00:18:01,160 --> 00:18:04,000
Speaker 1: So given all of that and the shift of drug

329
00:18:04,080 --> 00:18:07,600
Speaker 1: manufacturing to Asia where they're able to make more of

330
00:18:07,640 --> 00:18:09,800
Speaker 1: it for cheaper, why are we having shortages?

331
00:18:10,640 --> 00:18:13,960
Speaker 3: There are a lot of different reasons for drug shortages.

332
00:18:14,400 --> 00:18:17,880
Speaker 3: The primary one, FDA says six and ten drug shortages

333
00:18:17,920 --> 00:18:22,720
Speaker 3: are caused by quality problems, So that might be a

334
00:18:22,760 --> 00:18:26,399
Speaker 3: contamination and a batch or a lack of appropriate active

335
00:18:26,400 --> 00:18:29,080
Speaker 3: pharmaceutical ingredient. There are a lot of different reasons that

336
00:18:29,119 --> 00:18:33,080
Speaker 3: can spur a manufacturing or quality issue, but that is

337
00:18:33,119 --> 00:18:34,000
Speaker 3: the biggest driver.

338
00:18:35,000 --> 00:18:36,879
Speaker 1: And so when a drug has to be pulled out

339
00:18:36,920 --> 00:18:40,400
Speaker 1: the market because of a quality problem, do they relatively

340
00:18:40,480 --> 00:18:42,600
Speaker 1: quickly fix it and get it back on the shelves?

341
00:18:43,359 --> 00:18:45,639
Speaker 3: No wes. A year and a half is the average

342
00:18:45,720 --> 00:18:48,560
Speaker 3: duration of a drug shortage. According to a Homeland Security

343
00:18:48,600 --> 00:18:52,200
Speaker 3: and Government Affairs Committee report, sixty percent of drug shortages

344
00:18:52,480 --> 00:18:56,360
Speaker 3: are caused by underlying quality or manufacturing issues. If there

345
00:18:56,440 --> 00:18:58,560
Speaker 3: is something so severe that a product has to be

346
00:18:58,600 --> 00:19:00,760
Speaker 3: pulled from the market, it could be a while before

347
00:19:00,760 --> 00:19:05,520
Speaker 3: a shortage is resolved. Another reason for shortages is outright discontinuation.

348
00:19:05,840 --> 00:19:09,439
Speaker 3: So say you used to have five producers of a

349
00:19:09,480 --> 00:19:13,280
Speaker 3: specific generic drug and two of them get out of

350
00:19:13,280 --> 00:19:16,640
Speaker 3: that business because it's no longer profitable for them. That's

351
00:19:16,680 --> 00:19:19,800
Speaker 3: fewer production to meet the demand that exists. And then

352
00:19:19,840 --> 00:19:23,840
Speaker 3: another one might be delays that are faced. Maybe you're

353
00:19:23,880 --> 00:19:27,040
Speaker 3: not necessarily keeping up with a surge in demand over

354
00:19:27,200 --> 00:19:30,760
Speaker 3: say respiratory season, which we're now entering. If a lot

355
00:19:30,800 --> 00:19:33,280
Speaker 3: more people are seeking a certain drug and there's only

356
00:19:33,280 --> 00:19:35,400
Speaker 3: so many manufacturers, they might not be able to keep

357
00:19:35,480 --> 00:19:38,040
Speaker 3: up with demand too. So lots of different reasons for

358
00:19:38,200 --> 00:19:40,359
Speaker 3: drug shortages in the US. And I want to be

359
00:19:40,480 --> 00:19:44,040
Speaker 3: clear even as we discuss some of the challenges that

360
00:19:44,119 --> 00:19:47,840
Speaker 3: FDA has an oversight of the pharmaceutical supply chain that

361
00:19:47,920 --> 00:19:50,800
Speaker 3: exists abroad. That's not to say there aren't those quality

362
00:19:50,840 --> 00:19:53,840
Speaker 3: issues here in the United States as well. So it

363
00:19:54,040 --> 00:19:57,640
Speaker 3: exists in both places. And one of the underlying problems

364
00:19:57,680 --> 00:20:00,560
Speaker 3: is a lot of these companies don't have the money

365
00:20:00,560 --> 00:20:05,480
Speaker 3: to invest in advanced manufacturing, in automating systems. They leave

366
00:20:05,560 --> 00:20:08,800
Speaker 3: room for human error and to upgrade the facilities so

367
00:20:08,840 --> 00:20:11,720
Speaker 3: that it runs like a tight ship. Like over at

368
00:20:11,760 --> 00:20:15,040
Speaker 3: Pfizer where they make the vaccine, they don't have Pfizer's money,

369
00:20:15,119 --> 00:20:19,239
Speaker 3: they can't make those same investments. Pfizer has invested so

370
00:20:19,400 --> 00:20:23,080
Speaker 3: much money in production of the COVID vaccine with many

371
00:20:23,119 --> 00:20:26,000
Speaker 3: facilities here in the United States. That is a product

372
00:20:26,080 --> 00:20:28,840
Speaker 3: that has made tens of billions of dollars on an

373
00:20:28,880 --> 00:20:33,000
Speaker 3: annual basis. The COVID vaccine and its COVID therapeutic doubled

374
00:20:33,160 --> 00:20:35,680
Speaker 3: its revenue in a single year, so they can feed

375
00:20:35,720 --> 00:20:38,840
Speaker 3: that money back into the process. With generic drugs that

376
00:20:39,240 --> 00:20:41,959
Speaker 3: only cost cents on the dollar or a few dollars

377
00:20:41,960 --> 00:20:45,360
Speaker 3: at that, you don't have the same capital to reinvest

378
00:20:45,359 --> 00:20:48,439
Speaker 3: in the manufacturing process, and a lot of companies end

379
00:20:48,520 --> 00:20:49,320
Speaker 3: up cutting corners.

380
00:20:52,800 --> 00:20:55,560
Speaker 1: Are there safety risks to having so many of the

381
00:20:55,640 --> 00:20:59,240
Speaker 1: drugs that we take manufactured overseas where say the FDA

382
00:20:59,359 --> 00:21:02,080
Speaker 1: doesn't have as much oversight into them, or is that

383
00:21:02,240 --> 00:21:03,240
Speaker 1: not really a problem?

384
00:21:03,840 --> 00:21:07,080
Speaker 3: It is increasingly a problem, and it's one that we

385
00:21:07,119 --> 00:21:09,600
Speaker 3: at Bloomberg have taken a lot of time to examine

386
00:21:09,600 --> 00:21:12,960
Speaker 3: this year. There is evidence of generic drug makers abroad

387
00:21:12,960 --> 00:21:15,760
Speaker 3: cutting corners to keep costs down and evade being caught

388
00:21:15,880 --> 00:21:18,879
Speaker 3: for quality issues. So this year alone, our colleagues have

389
00:21:18,920 --> 00:21:23,040
Speaker 3: written about contaminated eye drops, poisoned coft syuroup which is

390
00:21:23,480 --> 00:21:25,919
Speaker 3: over the counter, and low quality abortion pills. I mean,

391
00:21:25,960 --> 00:21:28,360
Speaker 3: there are a number of cases the FDA would say,

392
00:21:28,359 --> 00:21:32,760
Speaker 3: trust your generic drugs. But Congress is certainly looking at

393
00:21:32,760 --> 00:21:37,040
Speaker 3: this question and pushing for more inspections abroad and other

394
00:21:37,240 --> 00:21:42,560
Speaker 3: forms of oversight and investment that will ensure quality moving forward.

395
00:21:43,760 --> 00:21:46,960
Speaker 1: When we come back, will the Biden administration give a

396
00:21:47,119 --> 00:21:58,000
Speaker 1: boost to generic drug makers? So if there is an

397
00:21:58,040 --> 00:22:03,000
Speaker 1: advantage both from a production standandpoint and for quality control

398
00:22:03,119 --> 00:22:06,920
Speaker 1: to have these medicines made in the US, but US

399
00:22:07,000 --> 00:22:10,160
Speaker 1: manufacturers can't afford to make a lot of them, what's

400
00:22:10,200 --> 00:22:13,119
Speaker 1: the solution here? How do we actually solve this problem?

401
00:22:13,600 --> 00:22:16,679
Speaker 3: I wish I had the conclusive answer to that question.

402
00:22:16,800 --> 00:22:19,280
Speaker 3: A lot of different stakeholders are now coming to the table,

403
00:22:19,960 --> 00:22:23,320
Speaker 3: particularly because of these acute drug shortages that have affected

404
00:22:23,640 --> 00:22:29,000
Speaker 3: life saving medicines like chemotherapies or basic antibiotics, to present

405
00:22:29,040 --> 00:22:32,960
Speaker 3: a solution. Many Congress people are pulling together legislation right

406
00:22:33,000 --> 00:22:36,080
Speaker 3: now to bolster US domestic drug production, and some of

407
00:22:36,080 --> 00:22:40,600
Speaker 3: the ideas include US health programs awarding contracts to US

408
00:22:40,640 --> 00:22:43,679
Speaker 3: based companies. That's one idea floating out there, calls to

409
00:22:43,720 --> 00:22:47,200
Speaker 3: actually increase prices of generic drugs. It's funny to say

410
00:22:47,240 --> 00:22:49,960
Speaker 3: that aloud, given so much of the discussion is about

411
00:22:50,440 --> 00:22:53,840
Speaker 3: lowering the cost of brand name pharmaceuticals, but again, this

412
00:22:53,880 --> 00:22:58,919
Speaker 3: is a totally different beast. Another is improving transparency in

413
00:22:58,920 --> 00:23:03,240
Speaker 3: the supply chain, simply having better data as to where

414
00:23:03,240 --> 00:23:07,040
Speaker 3: the supply is coming from up and downstream. We don't

415
00:23:07,080 --> 00:23:09,320
Speaker 3: want to just know where the generic is produced, we

416
00:23:09,359 --> 00:23:12,880
Speaker 3: want to know where the active pharmaceutical ingredients that underlie

417
00:23:12,920 --> 00:23:16,720
Speaker 3: that generic are made, and even the raw materials beneath that.

418
00:23:17,119 --> 00:23:20,359
Speaker 3: Having more visibility into the supply chain and a sense

419
00:23:20,400 --> 00:23:23,960
Speaker 3: of how many manufacturers exist, where they are, what kind

420
00:23:24,000 --> 00:23:27,280
Speaker 3: of quality issues they may have had in the past,

421
00:23:27,600 --> 00:23:30,040
Speaker 3: goes a long way to ensuring the security of the

422
00:23:30,080 --> 00:23:35,080
Speaker 3: supply chain. Another would be then taking those manufacturers and

423
00:23:35,200 --> 00:23:38,640
Speaker 3: ensuring they are properly registered with the FDA, And then

424
00:23:38,680 --> 00:23:42,400
Speaker 3: of course talk of grants, tax incentives, and loans.

425
00:23:43,280 --> 00:23:45,760
Speaker 1: We've also seen from the Biden administration a lot of

426
00:23:45,800 --> 00:23:48,480
Speaker 1: money to try to bring them manufacturing back to the US.

427
00:23:48,880 --> 00:23:52,440
Speaker 1: Is there any thought of putting that kind of incentives

428
00:23:52,520 --> 00:23:54,120
Speaker 1: into generic drugs as well.

429
00:23:54,840 --> 00:23:57,720
Speaker 3: Earlier this year we reported on a secret White House

430
00:23:57,800 --> 00:24:01,760
Speaker 3: effort to tackle this very qui question of how to

431
00:24:02,119 --> 00:24:05,800
Speaker 3: resolve drug shortages and underline quality issues that are driving them.

432
00:24:06,440 --> 00:24:08,800
Speaker 3: The team was formed by two White House bodies, the

433
00:24:08,880 --> 00:24:12,600
Speaker 3: National Economic Council and the Domestic Policy Council, with support

434
00:24:12,680 --> 00:24:15,200
Speaker 3: from other parts of the White House, and they were

435
00:24:15,200 --> 00:24:18,679
Speaker 3: really looking at this as a economic question, how do

436
00:24:18,760 --> 00:24:21,680
Speaker 3: we support industry. Some of the things that they were

437
00:24:21,680 --> 00:24:26,960
Speaker 3: thinking about were these tax incentives grants. Another novel concept

438
00:24:27,040 --> 00:24:30,840
Speaker 3: was doing third party quality assessment, saying, hey, are there

439
00:24:30,880 --> 00:24:34,040
Speaker 3: outsiders that we can bring to the table that can

440
00:24:34,080 --> 00:24:37,800
Speaker 3: examine the pharmaceutical supply chain and say we see a

441
00:24:37,800 --> 00:24:40,480
Speaker 3: problem here. But it remains to be seen whether or

442
00:24:40,560 --> 00:24:44,320
Speaker 3: not they will achieve something at the scale of say chips,

443
00:24:44,720 --> 00:24:48,920
Speaker 3: the Chips Act, which was about bringing chips production back

444
00:24:48,960 --> 00:24:51,679
Speaker 3: here to the United States, among many other things. But

445
00:24:52,200 --> 00:24:55,919
Speaker 3: we have not seen a Chips for pharma, despite people

446
00:24:55,920 --> 00:24:58,520
Speaker 3: advocating for it, and despite folks at the White House

447
00:24:58,600 --> 00:25:03,200
Speaker 3: really thinking critically about all the different ways to approach

448
00:25:03,359 --> 00:25:04,119
Speaker 3: this problem.

449
00:25:04,720 --> 00:25:06,800
Speaker 1: So we have a secret task urse inside the White House.

450
00:25:06,800 --> 00:25:08,280
Speaker 1: Why does it have to be secret?

451
00:25:08,640 --> 00:25:09,800
Speaker 3: That's a good question, Wes.

452
00:25:11,240 --> 00:25:13,280
Speaker 4: No answer there, No answer.

453
00:25:12,960 --> 00:25:16,840
Speaker 1: There, sirre Lely, I got to ask you. You must be

454
00:25:16,840 --> 00:25:19,000
Speaker 1: a whole lot of fun to watch TV with when

455
00:25:19,200 --> 00:25:20,560
Speaker 1: a pharmaceutical ad comes on.

456
00:25:21,119 --> 00:25:22,359
Speaker 4: Oh yeah, oh yeah.

457
00:25:22,400 --> 00:25:25,919
Speaker 3: I mean many of those drugs I knew like the

458
00:25:25,960 --> 00:25:28,760
Speaker 3: back of my hand for a while, because that's what

459
00:25:29,000 --> 00:25:32,080
Speaker 3: my beat was at Bloomberg was reporting on the blockbusters,

460
00:25:32,119 --> 00:25:34,600
Speaker 3: the new to market drugs that were trying to reap

461
00:25:34,640 --> 00:25:37,000
Speaker 3: as much as they could in sales in that specific

462
00:25:37,040 --> 00:25:40,960
Speaker 3: window before patent expires. You will never see it and

463
00:25:41,359 --> 00:25:44,439
Speaker 3: add on television for a generic drug. It's just not

464
00:25:44,560 --> 00:25:47,080
Speaker 3: how it works. So if you're seeing something on TV

465
00:25:47,560 --> 00:25:50,240
Speaker 3: that is a brand name product that has got a

466
00:25:50,280 --> 00:25:53,560
Speaker 3: totally different business model than the generics that might be

467
00:25:53,600 --> 00:25:55,360
Speaker 3: in your medicine cabinet.

468
00:25:55,400 --> 00:25:57,920
Speaker 1: Riley always great talking with you. Thanks for taking the time,

469
00:25:58,119 --> 00:26:01,320
Speaker 1: Thanks Wes, Thanks for listening to us here at the

470
00:26:01,320 --> 00:26:04,520
Speaker 1: Big Take. It's a daily podcast from Bloomberg and iHeartRadio.

471
00:26:04,840 --> 00:26:08,919
Speaker 1: For more shows from iHeartRadio, visit the iHeartRadio app, Apple Podcasts,

472
00:26:08,960 --> 00:26:11,479
Speaker 1: or wherever you listen and we'd love to hear from you.

473
00:26:11,720 --> 00:26:14,760
Speaker 1: Email us questions or comments to Big Take at Bloomberg

474
00:26:14,800 --> 00:26:17,879
Speaker 1: dot net. The supervising producer of The Big Take is

475
00:26:18,000 --> 00:26:22,280
Speaker 1: Vicky Bergolino. Our senior producer is Katherine Fink. This episode

476
00:26:22,320 --> 00:26:26,440
Speaker 1: was produced by Sam Gebauer and Christine Driscoll. Hilde Garcia

477
00:26:26,560 --> 00:26:30,240
Speaker 1: is our engineer. Our original music was composed by Leo Sidrin.

478
00:26:30,600 --> 00:26:33,720
Speaker 1: I'm West Kasova. We'll be back tomorrow with another Big

479
00:26:33,760 --> 00:26:34,000
Speaker 1: Take